NEWARK, DE -- (Marketwired) -- 10/03/14 -- iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced, as required by Section 610(b) of the NYSE MKT Company Guide, that the Company's Annual Report on Form 10-K was filed with the Securities and Exchange Commission on September 29, 2014, and that its audited consolidated financial statements for the fiscal year ended June 30, 2014 contained therein included a going concern qualification from its independent public accounting firm. This announcement does not represent any change or amendment to the Company's financial statements or to its Annual Report on Form 10-K for the fiscal year ended June 30, 2014. The Company recommends examination of the Company's complete Annual Report for a better understanding of the Company and its audited consolidated financial statements.
About iBio, Inc.
iBio is developing a proprietary product, IBIO-CFB03, for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis, and other fibrotic diseases using its iBioLaunch™ platform. The company also offers proprietary products and product licenses to others, based on its proprietary iBioLaunch and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology.
The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect. Further information is available at: www.ibioinc.com.
Investor Relations Contact
Ron Both
Liolios Group, Inc.
Tel 949-574-3860
Email Contact
